When was ObsEva founded?

ObsEva was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is ObsEva located?

ObsEva is headquartered in Geneva, Switzerland.

How many employees does ObsEva have?

As of Mar 01, 2026, the latest employee count at ObsEva is 10 - 49.

Is ObsEva a funded company?

ObsEva is a funded company, having raised a total of $94.7M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 29, 2013.

When was the latest funding round of ObsEva?

ObsEva's latest funding was a $***** Post IPO round on Sep 03, 2020, with participation from 0 investor. Its primary sector is Women Health. Globally, the Women Health sector has seen $204M in funding in 2026 to date.

What is the annual revenue of ObsEva?

Annual revenue of ObsEva is between $10M and $50M as on Dec 31, 2022

Where does ObsEva rank among its competitors?

ObsEva ranks 8th amongst 36 active competitors, of which 11 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Rejoni, which secured $25M in Jun, 2026.

Who are the top competitors of ObsEva?

ObsEva's top competitors include Rejoni, Gameto and Sprout Pharmaceuticals. Among them, Rejoni secured the most recent funding round in June, 2026.

ObsEva - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for women's reproductive health and pregnancy. Its lead candidate is Linzagolix an orally active gonadotropin-releasing hormone and receptor antagonist for Fibroids and Endometriosis. It also has two receptor antagonists Ebopiprant and Nolasiban for preterm labor.

Key Metrics

Founded Year

2012

Location

Geneva, Switzerland

Stage

Public

Total Funding

$94.7M in 6 rounds

Latest Funding Round

Post IPO, Sep 03, 2020, $*****

Investors

Sofinnova Partners & 18 more

Ranked

8^th among 36 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2022

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Rejoni & 35 more

Exit Details

Public

View ObsEva's full profile

ObsEva is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
OBSEVA SA CIN: 1685316 , United States, Active	Sep 08, 2016	$10M - $50M (As on Dec 31, 2022)	-	-

ObsEva got listed on Jan 26, 2017.

Click here to take a look at ObsEva's IPO in detail

ObsEva has raised a total funding of $94.7M over 6 rounds. Its first funding round was on Aug 29, 2013. ObsEva has 19 institutional investors.

Here is the list of recent funding rounds of ObsEva:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 03, 2020	9008634	Post IPO	5289140	3075784	5399402	8530416
Aug 07, 2019	5478283	Conventional Debt	6245852	8981497	8168617	Oxford Finance
Oct 10, 2017	8571127	Post IPO	4092732	4946292	7605581	New Enterprise Associates & 7 more

Access funding benchmarks and valuations. Sign up today!

View details of ObsEva's funding rounds and investors

The founders of ObsEva is Ernest Loumaye.

Here are the details of ObsEva's key team members:

Ernest Loumaye: Founder & CEO of ObsEva and founder of 1 other company.

View details of ObsEva's Founder profiles and Board Members

ObsEva's employee count trend

ObsEva has 10 - 49 employees as of Mar 26. Here is ObsEva's employee count trend over the years:

Uncover ObsEva's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ObsEva include Rejoni, Gameto and Sprout Pharmaceuticals. Here is the list of Top 10 competitors of ObsEva, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rejoni 2020, Bedford (United States), Series B	Developer of therapeutics to treat women health conditions	$66.3M	Ascension Ventures, CHV & 8 others	61/100
2nd	Gameto 2020, United States, Series C	Developer of therapeutics for the treatment of fertility and menopause	$127M	RA Capital Management, Two Sigma Ventures ... & 30 others	57/100
3rd	Sprout Pharmaceuticals 2011, Raleigh (United States), Acquired	Developer of drugs for hypoactive sexual desire disorder in women	$185M	New Ventures Funds, Lunsford Capital & 1 others	57/100
4th	Hope Medicine 2018, Shanghai (China), Series B	Developer of monoclonal antibodies for the treatment of multiple diseases	$56M	Qiming Venture Partners, Ennovation Ventures ... & 7 others	56/100
5th	Naari 2007, Noida (India), Acquired	Manufacturer of women care medicines	$19M	Ascent Capital, Jagsonpal & 18 others	52/100
6th	FimmCyte 2022, Basel (Switzerland), Funding Raised	Developer of therapeutics to treat endometriosis	-	BaseLaunch, Venture Kick & 2 others	45/100
7th	PregLem 2006, Geneva (Switzerland), Acquired	Drugs for women's reproductive medicine	$57.9M	MVM, NeoMed & 2 others	44/100
8th	ObsEva 2012, Geneva (Switzerland), Public	Developer of therapeutics for women's reproductive health and pregnancy	$94.7M	New Leaf Venture Partners, Aisling Capital ... & 17 others	44/100
9th	Forendo Pharma 2013, Turku (Finland), Acquired	Provider of small molecule based therapeutics for reproductive health	$25.6M	Sunstone, Novo Holdings & 8 others	44/100
10th	Aptorum Group 2017, London (United Kingdom), Public	Developer of small molecular therapeutics for multiple disorders	-	Aenco	43/100